Bone Biologics Company Top Insiders
| BBLG Stock | USD 0.96 0.01 1.03% |
Bone Biologics employs about 2 people. The company is managed by 3 executives with a total tenure of roughly 20 years, averaging almost 6.0 years of service per executive, having 0.67 employees per reported executive. Examination of Bone Biologics' management performance can provide insight into the company performance.
| Jeffrey Frelick CEO CEO President |
Bone |
Bone Biologics Management Team Effectiveness
The company has return on total asset (ROA) of (0.5725) % which means that it has lost $0.5725 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1903) %, meaning that it created substantial loss on money invested by shareholders. Bone Biologics' management efficiency ratios could be used to measure how well Bone Biologics manages its routine affairs as well as how well it operates its assets and liabilities.Bone Biologics Workforce Comparison
Bone Biologics Corp is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 658. Bone Biologics adds roughly 2.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Bone Biologics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bone Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bone Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bone Biologics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Deina Walsh six days ago Acquisition by Deina Walsh of 27055 shares of Bone Biologics at 0.9678 subject to Rule 16b-3 | ||
Soo B Chia over a month ago Disposition of 5274 shares by Soo B Chia of Bone Biologics at 1.58 subject to Rule 16b-3 | ||
Angle Siddhesh Rajendra over three months ago Acquisition by Angle Siddhesh Rajendra of 30713 shares of Bone Biologics at 1.73 subject to Rule 16b-3 | ||
Meikle Phillip Terry Ii over three months ago Insider Trading | ||
Gagnon Robert E. over three months ago Acquisition by Gagnon Robert E. of 30713 shares of Bone Biologics at 1.73 subject to Rule 16b-3 | ||
Angle Siddhesh Rajendra over three months ago Acquisition by Angle Siddhesh Rajendra of 30713 shares of Bone Biologics at 1.73 subject to Rule 16b-3 | ||
Deina Walsh over six months ago Acquisition by Deina Walsh of 11104 shares of Bone Biologics subject to Rule 16b-3 | ||
Gagnon Robert E. over six months ago Acquisition by Gagnon Robert E. of tradable shares of Bone Biologics at 4.68 subject to Rule 16b-3 |
Bone Biologics Notable Stakeholders
A Bone Biologics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bone Biologics often face trade-offs trying to please all of them. Bone Biologics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bone Biologics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jeffrey Frelick | CEO President | Profile | |
| Shunichi Kuroda | CoFounder Board | Profile | |
| Deina Walsh | Chief Officer | Profile |
About Bone Biologics Management Performance
The success or failure of an entity such as Bone Biologics Corp often depends on how effective the management is. Bone Biologics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bone management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bone management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company was founded in 2004 and is headquartered in Burlington, Massachusetts. Bone Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.
Bone Biologics Workforce Analysis
Traditionally, organizations such as Bone Biologics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bone Biologics within its industry.Bone Biologics Manpower Efficiency
Return on Bone Biologics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 4.5M | |
| Net Loss Per Executive | 3M | |
| Working Capital Per Employee | 1.5M | |
| Working Capital Per Executive | 968.8K |
Complementary Tools for Bone Stock analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |